uploads///Article

Products that Affect Merck’s Revenues

By

Jun. 22 2015, Updated 12:06 p.m. ET

Key products

Merck & Co. (MRK) recorded direct product sales of over $1 billion for each of its ten pharmaceutical products in the last year, listed below:

  • Gardasil
  • Isentress
  • Janumet
  • Januvia
  • Nasonex
  • ProQuad/Varivax
  • Remicade
  • Singulair
  • Vytorin
  • Zetia

These ten highly valued pharmaceutical products have contributed more than 54% of the total revenues of the Pharmaceuticals division in 2014, 52.6% in 2013, and 53.4% in 2012. The chart below shows the change in revenues for each of the ten key products over this timeframe.

Article continues below advertisement

Products at a glance

Januvia and Janumet are medicines used to lower blood sugar levels in adults with type 2 diabetes. In 2014, the combined sales for these two medicines totaled $6 billion, over 16.6% of the total pharmaceutical revenues for 2014. This growth was due to higher sales in the US and Europe.

Zetia and Vytorin are medicines used to lower LDL cholesterol levels. The combined sales for these two medicines amounted to $4.2 billion in 2014, a 3% decline compared with 2013. This decline was due to lower volumes of Vytorin in the US and Zetia in Canada, where they lost exclusivity.

Remicade is one of the top-selling drugs for the treatment of inflammatory diseases. This drug is marketed by MRK in Europe, Russia, and Turkey. Compared with 2013, its sales increased by 4% in 2014 to $2.4 billion, due to the increased volume in Europe and Russia. However, its sales are expected to decline after February 2015 due to the loss of market exclusivity in major European markets.

Singulair, a once-a-day oral medicine for asthma, lost its market exclusivity in US markets in August 2012 and in European markets in February 2013. There was a nearly 70% dip in total revenues of Singulair in 2013 and a nearly 9% decline in 2014.

Other companies like Pfizer (PFE), Eli Lilly (LLY), and Sanofi (SNY) compete with Merck on certain product mixes. The Health Care Select Sector SPDR ETF (XLV) has invested over 6.0% in Merck & Co.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.